Evidence mapPaperPMID 35955491Full record

ReviewInternational journal of molecular sciences2022

Crohn's Disease, Host-Microbiota Interactions, and Immunonutrition: Dietary Strategies Targeting Gut Microbiome as Novel Therapeutic Approaches.

María A Núñez-Sánchez, Silvia Melgar, Keith O'Donoghue, María A Martínez-Sánchez, Virgina E Fernández-Ruiz, Mercedes Ferrer-Gómez, Antonio J Ruiz-Alcaraz, Bruno Ramos-Molina

Open access · goldAbstract readReview
In one paragraph

Review in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
2.3field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 30 citations in OpenAlex.

  1. Journal of bacteriology · 2026
    Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Article
  7. Article
  8. Review
  9. Review
  10. Article
  11. Review
  12. Article
  13. Article
  14. Review
  15. Review
  16. Review
  17. Article
  18. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 2 countries.

María A Núñez-SánchezObesity and Metabolism Research Laboratory, Biomedical Research Institute of Murcia (IMIB), 30120 Murcia, Spain.
Silvia MelgarAPC Microbiome Ireland, University College Cork, T12 YT20 Cork, Ireland.ORCID 0000-0001-7463-3343
Keith O'DonoghueAPC Microbiome Ireland, University College Cork, T12 YT20 Cork, Ireland.
María A Martínez-SánchezObesity and Metabolism Research Laboratory, Biomedical Research Institute of Murcia (IMIB), 30120 Murcia, Spain.ORCID 0000-0001-9750-4237
Virgina E Fernández-RuizObesity and Metabolism Research Laboratory, Biomedical Research Institute of Murcia (IMIB), 30120 Murcia, Spain.
Mercedes Ferrer-GómezObesity and Metabolism Research Laboratory, Biomedical Research Institute of Murcia (IMIB), 30120 Murcia, Spain.
Antonio J Ruiz-AlcarazDepartment of Biochemistry and Molecular Biology B and Immunology, Faculty of Medicine, University of Murcia, 30120 Murcia, Spain.ORCID 0000-0001-6913-0610
Bruno Ramos-MolinaObesity and Metabolism Research Laboratory, Biomedical Research Institute of Murcia (IMIB), 30120 Murcia, Spain.ORCID 0000-0001-6804-5449
Instituto Murciano de Investigación Biosanitaria · ESUniversity College Cork · IEUniversidad de Murcia · ES

Funding

Instituto de Salud Carlos III CP19/00098Instituto de Salud Carlos III FI21/00003Instituto de Salud Carlos III PI20/00505Science Foundation Ireland SFI/12/RC/2273-P1Science Foundation Ireland SFI/12/RC/2273-P2
6 · The paper itself

Abstract

Crohn's disease (CD) is a complex, disabling, idiopathic, progressive, and destructive disorder with an unknown etiology. The pathogenesis of CD is multifactorial and involves the interplay between host genetics, and environmental factors, resulting in an aberrant immune response leading to intestinal inflammation. Due to the high morbidity and long-term management of CD, the development of non-pharmacological approaches to mitigate the severity of CD has recently attracted great attention. The gut microbiota has been recognized as an important player in the development of CD, and general alterations in the gut microbiome have been established in these patients. Thus, the gut microbiome has emerged as a pre-eminent target for potential new treatments in CD. Epidemiological and interventional studies have demonstrated that diet could impact the gut microbiome in terms of composition and functionality. However, how specific dietary strategies could modulate the gut microbiota composition and how this would impact host-microbe interactions in CD are still unclear. In this review, we discuss the most recent knowledge on host-microbe interactions and their involvement in CD pathogenesis and severity, and we highlight the most up-to-date information on gut microbiota modulation through nutritional strategies, focusing on the role of the microbiota in gut inflammation and immunity.

Indexed as

Crohn DiseaseGastrointestinal MicrobiomeMicrobiotaDietHost Microbial InteractionsHumansInflammationCrohn’s diseasedietgut microbiomeimmunonutritioninflammation

Identifiers

PMID35955491
PMCPMC9369148
OpenAlexW4288426977

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.